Bayer (BAYRY)
(Delayed Data from OTC)
$7.81 USD
+0.01 (0.13%)
Updated May 10, 2024 03:59 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BAYRY 7.81 +0.01(0.13%)
Will BAYRY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAYRY
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Other News for BAYRY
Bayer to present data from Kerendia trial program at Heart Failure 2024 Congress
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
AI-discovered drugs have an 80%–90% success rate: study
Elanco surges on Q1 beat, anticipated product launches
Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks